The Psychopharmacologic Drugs Advisory Committee will meet on Friday 17June 2022 to discuss supplemental new drug applications (sNDA) ( 210793-s008) and (207318-s011), efficacy supplement resubmission for NUPLAZID (pimavanserin) tablets, submitted by Acadia Pharmaceuticals Inc., for the proposed treatment of hallucinations and delusions associated with Alzheimer's disease psychosis.
Back to All Events
Earlier Event: June 15
Vaccines and Related Biological Products Advisory Committee
Later Event: June 28
Vaccines and Related Biological Products Advisory Committee